3.09
Cabaletta Bio Inc (CABA) 最新ニュース
H.C. Wainwright Remains a Buy on Cabaletta Bio (CABA) - The Globe and Mail
CABA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Cabaletta reports results, advances Rese-Cel autoimmune program - MSN
Cabaletta Bio, Inc. (CABA) Stock Forecasts - Yahoo! Finance Canada
Cabaletta Reports Results, Advances Rese-Cel Autoimmune Program - MyChesCo
Aug Summary: Can Cabaletta Bio Inc disrupt its industryBuy Signal & Low Drawdown Investment Ideas - baoquankhu1.vn
Cabaletta Bio Inc (MEX:CABA) Stock Price, Trades & News - GuruFocus
Cabaletta Bio Inc Stock Warning Signs - GuruFocus
Cabaletta Bio, Inc. (CABA) Stock forecasts - uk.finance.yahoo.com
Q1 EPS Estimates for Cabaletta Bio Raised by HC Wainwright - MarketBeat
Philly Biotech Co. Develops High-Potential Autoimmune Therapy Breakthrough - Streetwise Reports
HC Wainwright Weighs in on Cabaletta Bio Q1 Earnings - MarketBeat
CABA Stock Price, Quote & Chart | CABALETTA BIO INC (NASDAQ:CABA) - ChartMill
H.C. Wainwright Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $16 - Moomoo
H.C. Wainwright reiterates Cabaletta Bio stock rating at buy By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Cabaletta Bio stock rating at buy - Investing.com
Cabaletta Bio Inc. (CABA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Is Cabaletta Bio Incs ROIC above industry average2026 Weekly Recap & Technical Confirmation Trade Alerts - baoquankhu1.vn
Take Profit: What are Cabaletta Bio Incs recent SEC filings showingPortfolio Update Summary & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Cabaletta Bio (NASDAQ:CABA) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Cabaletta Bio, Inc.Common Stock (NQ: CABA - markets.financialcontent.com
This Biotech Stock Could Deliver 350% Returns in 12 Months - GuruFocus
Jefferies reiterates Cabaletta Bio stock rating on product profile By Investing.com - Investing.com India
Jefferies reiterates Cabaletta Bio stock rating on product profile - investing.com
Aug Retail: What is Cabaletta Bio Incs P E ratio telling usPortfolio Profit Report & Capital Efficient Trading Techniques - baoquankhu1.vn
Guggenheim Forecasts Strong Price Appreciation for Cabaletta Bio (NASDAQ:CABA) Stock - marketbeat.com
Morgan Stanley Cuts Cabaletta Bio (NASDAQ:CABA) Price Target to $13.00 - MarketBeat
Analyst Michael Ulz Lowers Price Target for Cabaletta Bio (CABA) to $13 | CABA Stock News - GuruFocus
A Quick Look at Today's Ratings for Cabaletta Bio(CABA.US), With a Forecast Between $13 to $14 - Moomoo
Pfizer To Rally More Than 34%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Guggenheim raises Cabaletta Bio stock price target on trial progress By Investing.com - Investing.com India
Jefferies reiterates Buy on Cabaletta Bio stock, $14 target By Investing.com - Investing.com Australia
Cabaletta Bio price target lowered to $13 from $14 at Morgan Stanley - TipRanks
Jefferies reiterates Buy on Cabaletta Bio stock, $14 target - Investing.com UK
William Blair reiterates Outperform on Cabaletta Bio stock By Investing.com - ca.investing.com
CABA Advances with Innovative Therapeutic Approaches - GuruFocus
Guggenheim raises Cabaletta Bio stock price target on trial progress - Investing.com
Cabaletta Bio Reports 2025 Financial Results, Highlights Progress on Rese-cel CAR-T Cell Therapy and Upcoming Clinical Milestones - minichart.com.sg
Jefferies Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $14 - Moomoo
大文字化:
|
ボリューム (24 時間):